SRX-251

N/A

Report date: 2022/11/25 17:18:48
NME

Base Information

Drug NameSRX-251
Drug Alias NameAPI-251SRX-251
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V1a receptor antagonists
TargetsVasopressin V1a receptor
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAzevan
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAzevan Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A